

Banzel (Rufinamide) Criteria

Revised: 07/10/2024

BANZEL (RUFINAMIDE)

Length of Authorization: 1 year

CHILDREN – CRITERIA TO APPROVE

All the following:

- Age > 1 year
- Diagnosis of adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)
- Prescriber is a neurologist or consult notes from a neurology office are provided.

ADULTS – CRITERIA TO APPROVE

All the following:

- Age ≥ 18 years
- Diagnosis of adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)
- Prescriber is a neurologist or consult notes from a neurology office are provided.

ADULTS – RENEWAL CRITERIA

All the following:

- Member is responding well to therapy.
- Patient has not experienced any treatment-restricting adverse effects.

REVISION HISTORY

Date	Issues/Updates
07/10/2024	• Initial draft creation

Orange Text = Important Information | **Teal Text = Auto PA**

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Banzel (Rufinamide) Criteria

Page 2